312 related articles for article (PubMed ID: 31216704)
21. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation.
Kalva S; Agrawal N; Skelton AA; Saleena LM
Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644
[TBL] [Abstract][Full Text] [Related]
22. Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke RE; Libert C
Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of ferulic Acid amides as selective matrix metalloproteinase inhibitors.
Shi ZH; Li NG; Shi QP; Tang H; Tang YP; Li W; Yin L; Yang JP; Duan JA
Med Chem; 2013 Nov; 9(7):947-54. PubMed ID: 23061601
[TBL] [Abstract][Full Text] [Related]
24. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
25. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2004 Nov; 11(22):2911-77. PubMed ID: 15544483
[TBL] [Abstract][Full Text] [Related]
26. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
[TBL] [Abstract][Full Text] [Related]
27. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases.
Aureli L; Gioia M; Cerbara I; Monaco S; Fasciglione GF; Marini S; Ascenzi P; Topai A; Coletta M
Curr Med Chem; 2008; 15(22):2192-222. PubMed ID: 18781944
[TBL] [Abstract][Full Text] [Related]
28. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment.
Stellas D; Patsavoudi E
Anticancer Agents Med Chem; 2012 Sep; 12(7):707-17. PubMed ID: 22292747
[TBL] [Abstract][Full Text] [Related]
30. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
Maskos K; Bode W
Mol Biotechnol; 2003 Nov; 25(3):241-66. PubMed ID: 14668538
[TBL] [Abstract][Full Text] [Related]
31. Molecular insights in repurposing selective COX-2 inhibitor celecoxib against matrix metalloproteinases in potentiating delayed wound healing: a molecular docking and MMPB/SA based analysis of molecular dynamic simulations.
Mude L; Jupudi S; Swaroop AK; Tallapaneni V; Karri VVSR
J Biomol Struct Dyn; 2024 Mar; 42(5):2437-2448. PubMed ID: 37160705
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
33. Methods for the Construction of Collagen-Based Triple-Helical Peptides Designed as Matrix Metalloproteinase Inhibitors.
Fields GB
Methods Mol Biol; 2019; 1944():229-252. PubMed ID: 30840247
[TBL] [Abstract][Full Text] [Related]
34. Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.
Ammazzalorso A; De Filippis B; Campestre C; Laghezza A; Marrone A; Amoroso R; Tortorella P; Agamennone M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782083
[TBL] [Abstract][Full Text] [Related]
35. Progress in the development of matrix metalloproteinase inhibitors.
Tu G; Xu W; Huang H; Li S
Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
[TBL] [Abstract][Full Text] [Related]
36. Quest for selectivity in inhibition of matrix metalloproteinases.
Brown S; Meroueh SO; Fridman R; Mobashery S
Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
[TBL] [Abstract][Full Text] [Related]
37. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
Ramezani M; Shamsara J
Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
[TBL] [Abstract][Full Text] [Related]
38. The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.
Fields GB
Cells; 2019 Aug; 8(9):. PubMed ID: 31461880
[TBL] [Abstract][Full Text] [Related]
39. An integrated structure- and pharmacophore-based MMP-12 virtual screening.
Ramezani M; Shamsara J
Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648
[TBL] [Abstract][Full Text] [Related]
40. Mechanism and Inhibition of Matrix Metalloproteinases.
Cerofolini L; Fragai M; Luchinat C
Curr Med Chem; 2019; 26(15):2609-2633. PubMed ID: 29589527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
